> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Voyager Therapeutics Corrects Earnings Classification — Its Reported Results Stay Unchanged
- URL: https://www.bullished.co/voyager-therapeutics-corrects-earnings-classification-its-reported-results-stay-unchanged-e0087ac2/
- Published: 2026-11-18T22:06:46.000Z
- Updated: 2026-11-18T22:06:46.000Z
- Description: The correction leaves intact Voyager’s earlier cash outlook and plans for Alzheimer’s trial data.
- Author: Matteo Parrino
- Tags: Earnings, VYGR, Industry: Healthcare

[Voyager Therapeutics](https://www.bullished.co/tag/vygr/), which develops genetic medicines for neurological diseases, has now disclosed a [submission-classification correction](https://www.sec.gov/Archives/edgar/data/0001640266/000119312526467226/d184454d8ka.htm?ref=bullished.co) in an amended SEC filing Wednesday. Its previously reported third-quarter results and corporate updates remain unchanged.

## An Earnings Report, Not An Asset Deal

Voyager’s [original report](https://www.sec.gov/Archives/edgar/data/0001640266/000119312526449728/vygr-20261105.htm?ref=bullished.co), filed November 5, already identified the disclosure correctly as financial results and exhibits. The error was in the electronic submission header, which categorized it as an asset transaction.

Wednesday’s amendment corrected that header to match the report. Voyager left the original disclosure intact, without updating it for subsequent events.

## Lower Spending Extended The Funding Outlook

The November 5 earnings release put [cash and investments](https://www.sec.gov/Archives/edgar/data/0001640266/000119312526449728/vygr-ex99%5F1.htm?ref=bullished.co) at $132.1 million as of September 30, compared with $201.7 million at the end of 2025\. Voyager expects those resources, anticipated collaboration reimbursements and interest income to fund planned operations and capital spending into the second quarter of 2028.

Chief Executive Officer Alfred W. Sandrock, Jr. tied the longer funding outlook to spending cuts. “During the third quarter, we continued to be disciplined in our operations to reduce year-over-year operating expenses and as a result, we have extended our cash runway into the second quarter of 2028,” he said in the [earnings release](https://www.sec.gov/Archives/edgar/data/0001640266/000119312526449728/vygr-ex99%5F1.htm?ref=bullished.co).

Research and development spending fell to $24.4 million from $35.9 million a year earlier. Voyager attributed the decline mainly to lower clinical and manufacturing costs and decisions about which programs to prioritize. Administrative spending fell to $6.1 million from $8.1 million, which it attributed chiefly to lower employee and consulting costs.

Collaboration revenue declined to $4.0 million from $13.4 million. Voyager said less revenue was recognized from its Neurocrine Biosciences partnership as activities moved beyond research. The quarterly net loss narrowed to $24.7 million, or $0.40 a share, from $27.9 million, or $0.47 a share.

Voyager earns money through partner fees, milestones and research reimbursements. Its own Alzheimer’s programs target tau with an antibody and a gene therapy; other programs advance with partners.

## Alzheimer’s Data And A Planned Succession

The earlier release said the final patient visit in Voyager’s Alzheimer’s antibody trial was complete. The company expects imaging results measuring tau in the fourth quarter of 2026.

Patient screening continues in the United States for its gene-therapy trial in adults with early Alzheimer’s. Voyager expects dosing to start in the next few months, pending enrollment, and initial acute safety data in the first quarter of 2027.

Neurocrine Biosciences, Voyager’s partner on a Friedreich’s ataxia gene therapy, expects that program to enter an early-stage clinical study in the coming months, followed by initial patient-level data in 2027.

Robin Swartz, appointed president on October 20, is expected to succeed Sandrock as CEO following receipt of the Alzheimer’s gene-therapy trial’s initial acute safety data.

Learn

- [8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples →](https://www.bullished.co/learn/8-k-items-explained/)  
What every common 8-K item means, from 1.01 to 9.01: which are routine, which are rare, what to check, with real examples and counts from 90 days of filings.

### Sources

- [8-K/A Filing (Amendment) — Voyager Therapeutics, Inc. (VYGR)](https://www.sec.gov/Archives/edgar/data/0001640266/000119312526467226/d184454d8ka.htm?ref=bullished.co) — SEC EDGAR
- [Original 8-K — Voyager Therapeutics, Inc. (filed 2026-11-05)](https://www.sec.gov/Archives/edgar/data/0001640266/000119312526449728/vygr-20261105.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit d184454dex991.htm — Voyager Therapeutics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001640266/000119312526467226/d184454dex991.htm?ref=bullished.co) — SEC EDGAR
- [8-K filed 2026-11-05 — Voyager Therapeutics, Inc. (earlier disclosure)](https://www.sec.gov/Archives/edgar/data/0001640266/000119312526449728/vygr-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR

### More on Voyager Therapeutics

- [Voyager Cuts Research Spending To $24.4 Million, Extends Funding Outlook Into 2028](https://www.bullished.co/voyager-cuts-research-spending-to-24-4-million-extends-funding-outlook-into-2028-ec1dad46/)
- [Voyager Therapeutics Names Robin Swartz President, Expects Her To Succeed CEO Alfred Sandrock](https://www.bullished.co/voyager-therapeutics-names-robin-swartz-president-expects-her-to-succeed-ceo-alfred-814a98c9/)

[All Voyager Therapeutics (VYGR) coverage →](https://www.bullished.co/tag/vygr/)